Apixaban (Eliquis) Timeline for Atrial Fibrillation
When to Start Apixaban
Start apixaban immediately upon diagnosis of atrial fibrillation requiring anticoagulation—no loading dose, bridging therapy, or delay is needed for chronic stroke prevention. 1
- Begin therapy as soon as the decision to anticoagulate is made; apixaban reaches therapeutic levels within 3–4 hours of the first dose due to its rapid absorption and onset of action. 2, 1
- For new-onset atrial fibrillation, simply initiate the appropriate dose based on the criteria below without any preparatory anticoagulation. 1
- If cardioversion is planned within 48 hours of AF onset, give at least one dose of apixaban ≥4 hours before the procedure (or ≥2 hours after an off-label 10 mg loading dose, though this is not part of official labeling). 2
- For AF duration >48 hours, either anticoagulate for ≥3 weeks before cardioversion, or perform transesophageal echocardiography to exclude left atrial thrombus before proceeding. 2
Dosing Regimen
Standard Dose: 5 mg Twice Daily
Prescribe apixaban 5 mg orally twice daily for most patients with atrial fibrillation, including those with moderate renal impairment (CrCl 30–59 mL/min). 2, 1, 3
Reduced Dose: 2.5 mg Twice Daily
Reduce to 2.5 mg twice daily ONLY when the patient meets at least TWO of the following three criteria: 2, 1, 3
- Age ≥80 years
- Body weight ≤60 kg
- Serum creatinine ≥1.5 mg/dL
- Meeting only one criterion does not justify dose reduction—this is the most common prescribing error with apixaban. 1
- Do not reduce the dose based on perceived frailty, fall risk, isolated moderate CKD, or clinician concern about bleeding unless the formal "2-of-3" criteria are met. 1
Special Renal Dosing
| Creatinine Clearance | Recommended Dose | Comment |
|---|---|---|
| >30 mL/min | 5 mg twice daily (unless ≥2 reduction criteria met) | Standard dosing [2,1] |
| 15–29 mL/min | 2.5 mg twice daily (mandatory for all patients) | Severe renal impairment alone mandates reduction [2,1] |
| <15 mL/min or dialysis | 5 mg twice daily; reduce to 2.5 mg twice daily if age ≥80 years OR weight ≤60 kg (only one criterion required) | FDA-approved for stable hemodialysis [1,3] |
- Always calculate creatinine clearance using the Cockcroft-Gault equation with actual body weight—eGFR is not interchangeable and will lead to dosing errors. 2, 1
Time to Therapeutic Anticoagulation
Apixaban achieves therapeutic anticoagulation within 3–4 hours of the first dose, with peak plasma levels at approximately 3 hours. 1
- No bridging with heparin or LMWH is required when starting apixaban for chronic atrial fibrillation. 1
- The drug reaches steady-state concentrations after approximately 3 days of twice-daily dosing. 1
- No routine INR monitoring is needed—apixaban provides predictable anticoagulation without laboratory surveillance. 2, 1
Critical Dose-Reduction Criteria Details
Age ≥80 Years
- This is one of the three criteria; age alone does not mandate dose reduction unless combined with weight ≤60 kg or serum creatinine ≥1.5 mg/dL. 2, 1
Body Weight ≤60 kg
- Weight must be recorded in kilograms, not pounds. 1
- Low weight alone does not trigger dose reduction—it must be paired with another criterion. 2, 1
Serum Creatinine ≥1.5 mg/dL
- This is the serum creatinine threshold, not a creatinine clearance cutoff. 2, 1
- A creatinine of 1.5 mg/dL is one criterion; if the patient also meets one other criterion (age ≥80 or weight ≤60 kg), reduce to 2.5 mg twice daily. 2, 1
Drug Interactions Requiring Dose Adjustment
Reduce apixaban from 5 mg to 2.5 mg twice daily when using combined P-glycoprotein AND strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir, itraconazole). 2, 1
Avoid apixaban entirely with strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin, St. John's wort) because they markedly lower apixaban levels. 2, 1
Monitoring Requirements
- Renal function: Reassess creatinine clearance at least annually in all patients; increase frequency to every 3–6 months when CrCl <60 mL/min. 2, 1
- No routine coagulation monitoring (INR, aPTT) is required. 2, 1
- Clinical vigilance for bleeding symptoms, especially gastrointestinal bleeding in older adults. 1
Common Pitfalls to Avoid
- Do not reduce the dose based on a single criterion—9.4–40.4% of apixaban prescriptions involve inappropriate underdosing, often driven by isolated renal impairment or perceived bleeding risk. 1
- Do not use eGFR for dosing decisions—always calculate CrCl with Cockcroft-Gault using actual body weight. 2, 1
- Do not empirically reduce the dose in patients with moderate CKD (CrCl 30–59 mL/min) unless they meet ≥2 of the formal criteria. 2, 1
- For severe renal impairment (CrCl 15–29 mL/min), the 2.5 mg twice-daily dose is mandatory for all patients, regardless of the "2-of-3" rule. 2, 1
Pharmacokinetic Advantage
Apixaban has only 27% renal clearance, making it the safest direct oral anticoagulant in renal impairment compared to dabigatran (≈80% renal) or rivaroxaban (≈66% renal). 2, 1, 4
- This low renal dependence provides a wider safety margin as kidney function declines and makes apixaban the preferred NOAC in moderate-to-severe CKD. 1, 4
- In the ARISTOTLE trial, apixaban reduced major bleeding by 31% versus warfarin, with the greatest relative benefit in patients with impaired renal function (CrCl ≤50 mL/min: HR 0.50). 1, 4